Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Malignancies in children and young adults on etanercept: summary of cases from clinical trials and post marketing reports
Michele Hooper, Deborah Wenkert, Bojena Bitman, et al.
Pediatric Rheumatology (2013) Vol. 11, Iss. 1
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Treatment of juvenile idiopathic arthritis: a revolution in care
Matthew L. Stoll, Randy Q. Cron
Pediatric Rheumatology (2014) Vol. 12, Iss. 1
Open Access | Times Cited: 161
Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases
Lesley J. Scott
Drugs (2014) Vol. 74, Iss. 12, pp. 1379-1410
Closed Access | Times Cited: 99
Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?
Yuehong Chen, Marcia Friedman, Gang Liu, et al.
Cytokine (2016) Vol. 101, pp. 78-88
Closed Access | Times Cited: 62
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial
Ivan Foeldvari, Tamás Constantin, Jelena Vojinović, et al.
Arthritis Research & Therapy (2019) Vol. 21, Iss. 1
Open Access | Times Cited: 38
An update ont the safety of biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis
A. Zimmer, Gerd Horneff
Expert Opinion on Drug Safety (2025)
Closed Access
Malignancy and the Risks of Biologic Therapies
Raphaèle Séror, Xavier Mariette
Rheumatic Disease Clinics of North America (2016) Vol. 43, Iss. 1, pp. 43-64
Closed Access | Times Cited: 27
Efficacy and safety of ustekinumab in adolescents
Jonathan I. Silverberg, Mark Lebwohl, Roselyn Kellen
Pediatric Health Medicine and Therapeutics (2016) Vol. Volume 7, pp. 109-120
Open Access | Times Cited: 19
Blueberry Improves the Therapeutic Effect of Etanercept on Patients with Juvenile Idiopathic Arthritis: Phase III Study
Yingjie Zhong, Ye Wang, Jun Guo, et al.
The Tohoku Journal of Experimental Medicine (2015) Vol. 237, Iss. 3, pp. 183-191
Open Access | Times Cited: 18
Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases
Celeste B. Burness, Sean T. Duggan
BioDrugs (2016) Vol. 30, Iss. 4, pp. 371-378
Closed Access | Times Cited: 14
Malignancy incidence in 5294 patients with juvenile arthritis
Omid Zahedi Niaki, Ann E. Clarke, Rosalind Ramsey‐Goldman, et al.
RMD Open (2016) Vol. 2, Iss. 1, pp. e000212-e000212
Open Access | Times Cited: 13
Medikamentöse Therapie der rheumatoiden Arthritis bei Malignomanamnese
Marc Schmalzing, Anja Strangfeld, H-P Tony
Zeitschrift für Rheumatologie (2016) Vol. 75, Iss. 1, pp. 22-31
Open Access | Times Cited: 6
Clinical utility of etanercept in the treatment of arthritides in children and adolescents
Robin K. Dore
Adolescent Health Medicine and Therapeutics (2014), pp. 35-35
Open Access | Times Cited: 4
Evidenz der Therapie chronisch-entzündlicher Erkrankungen in Kindheit und Adoleszenz mit Biologika
Hans‐Iko Huppertz, Hartwig Lehmann
Zeitschrift für Rheumatologie (2014) Vol. 73, Iss. 10, pp. 907-916
Closed Access | Times Cited: 3
Association between drug intake and incidence of malignancies in patients with Juvenile Idiopathic Arthritis: a nested case–control study
Swaantje Barth, Jenny Schlichtiger, Betty Bisdorff, et al.
Pediatric Rheumatology (2016) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Bone Tumors Developed in Patients with Juvenile Inflammatory Arthritis after Anti-Tnfα Therapy
Huihui Chi, Jialin Teng, Chengde Yang, et al.
Immunotherapy (2018) Vol. 10, Iss. 12, pp. 1033-1039
Closed Access | Times Cited: 3
Inflammation-targeted therapies and cancer
Joanna Kedra, Gaétane Nocturne, Xavier Mariette, et al.
Joint Bone Spine (2021) Vol. 88, Iss. 4, pp. 105176-105176
Open Access | Times Cited: 3
Arzneimittelsicherheit in der Kinderrheumatologie
Jens Klotsche, Martina Niewerth, Gerd Horneff, et al.
Arthritis und Rheuma (2014) Vol. 34, Iss. 01, pp. 42-47
Closed Access
Biologic therapies in systemic juvenile idiopathic arthritis
Ezgi Deniz Batu
Expert Opinion on Orphan Drugs (2016) Vol. 4, Iss. 6, pp. 621-629
Closed Access
Evidenz der Therapie chronisch-entzündlicher Erkrankungen in Kindheit und Adoleszenz mit Biologika
Klinikum Bremen-Mitte
(2014)
Closed Access
Artritis idiopática juvenil en el adulto joven. Metodología, objetivos y datos iniciales del registro JUVENSER
Juan José Bethencourt-Baute, Núria Montero, Andrea M. Zacarias, et al.
Reumatología Clínica (2023) Vol. 19, Iss. 6, pp. 328-333
Closed Access
Juvenile idiopathic arthritis in the young adult. Methodology, objectives, and initial data from the JUVENSER registry
Juan José Bethencourt-Baute, Núria Montero, Andrea M. Zacarias, et al.
Reumatología Clínica (English Edition) (2023) Vol. 19, Iss. 6, pp. 328-333
Closed Access
Skin Diseases Associated with Biologic Therapies
Sharon Rose, Shivani B. Kaushik, Mark Lebwohl
Springer eBooks (2017), pp. 155-165
Closed Access
Arzneimittelsicherheit bei der Therapie rheumatischer Erkrankungen im Kindes- und Jugendalter – Ergebnisse aus JuMBO
Jens Klotsche, Martina Niewerth, Kirsten Minden
Arthritis und Rheuma (2019) Vol. 39, Iss. 04, pp. 234-240
Closed Access
Systemic Therapy in Paediatric Dermatology
Blanca R. Del Pozzo‐Magaña, Irene Lara‐Corrales
Harper's Textbook of Pediatric Dermatology (2019), pp. 2282-2300
Closed Access
Malignancy Risks of Dermatologic Therapies
Kevin C.‐W. Wu, April W. Armstrong
Springer eBooks (2021), pp. 149-190
Closed Access
Page 1 - Next Page

Scroll to top